ArticleCurrent epidemiology reports2019
Sex Differences in Melanoma.
Article in Current epidemiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Melanoma evolution in the lymph node shapes systemic outcomes.bioRxiv : the preprint server for biology · 2026Article
- Age-specific melanoma risk associated with melanocytic nevi: a pooled analysis from the M-SKIP project.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Global skin cancer burden and United States mortality trends in younger adults (Aged 20-44 Years): An analysis of the Global Burden of Disease Study 2021 and CDC WONDER Databases.JID innovations : skin science from molecules to population health · 2026Article
- Antihypertensive Drugs as Potential Repositioning Options for Melanoma: A Map of Pre-Clinical Evidence.Diseases (Basel, Switzerland) · 2026Review
- Utilizing relative survival to investigate melanoma subtypes across intersectional demographics: a Surveillance, Epidemiology, and End Results (SEER) cohort study.Skin health and disease · 2026Article
- Geographic and population disparities in cutaneous melanoma in the United States: state-level trends and national population-level analyses.BMC public health · 2026Article
- Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.Oral oncology · 2026Article
- Transdermal Hormonal Therapy in Menopause: Current Evidence and Personalized Approaches.Pharmaceutics · 2026Review
- Transcriptional mechanisms of sex-biased gene expression and their connections to disease-associated variation.Human molecular genetics · 2026Article
- Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.Medicina (Kaunas, Lithuania) · 2026Article
- Skin Cancer in Solid Organ Transplant Recipients: A Review.American journal of clinical dermatology · 2026Review
- Long-term changes in melanoma epidemiology in Hungary: who are the high-risk groups, and where should we concentrate prevention programs?BMC public health · 2026Article
- A novel polymorphism in the TERT gene is associated with lower survival in male patients with melanoma.Molecular medicine (Cambridge, Mass.) · 2026Article
- Clinicopathological features and ethnic disparities of melanoma in the United Arab Emirates: 2017-2025.PloS one · 2026Article
- Diverging Incidence and Mortality of Cutaneous Melanoma in Mainland China, 1990-2023, with Projections to 2030: A Global Burden of Disease 2023 Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- When Jack of All Trades Is a Master of None: Comparing the Performance of GPT-4 Omni against Specialised Neural Networks in Identifying Malignant Dermatological Lesions from Smartphone Images and Structured Clinical Data.Dermatology (Basel, Switzerland) · 2026Article
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.Frontiers in medicine · 2026Article
- Melanoma in Women of Reproductive Age: From Awareness and Prevention to Pregnancy-Associated Management.Cancers · 2025Review
- Molecular Profiling and Tumor Microenvironment in Sinonasal Mucosal Melanoma as Biomarkers for Enhanced Prognostic Stratification.International forum of allergy & rhinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe goal of this review has been to elucidate the sex differences in cancer incidence and mortality in cutaneous melanoma. We have evaluated biological and behavioral research to determine where the critical questions exist. RECENT
findingsThe most recent findings, through 2015, are exploratory in nature but seem to indicate that the differences are more likely due to biological variations rather than behavioral. While behavioral studies do show that women are more likely than men to seek health care and practice healthy behaviors, these differences are not sufficiently strong to explain the variation in incidence and mortality in cutaneous melanoma. Evolved differences in the immune systems of females and the role of sex steroid hormones in immunomodulation are two promising avenues for research. Studies in mice demonstrate that the newer immunotherapies are more effective in females and sex steroid hormones, such as estrogen receptor beta are inversely associated with tumor aggressiveness while testosterone increases it. SUMMARY: Our analysis indicates that biological factors need to be investigated more thoroughly to understand the variation in incidence and mortality in cutaneous melanoma. Such understanding could lead to reducing incidence and mortality for both males and females (male incidence is 27.4 per 100,000; female 16.8 per 100,000; male mortality is 3.9 per 100,000; female mortality 1.6 per 100,000). It is most likely that behavioral differences between the sexes cannot account for the preponderance of male mortality. In addition to the important role of genetic factors, it is critical to evaluate further additional biological factors and their interactions with genetics and behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.